Notice NOT-CA-22-043 from the NIH Guide for Grants and Contracts

Notice NOT-DK-22-003 from the NIH Guide for Grants and Contracts

£46,199-£55,341 per annum: Wellcome Sanger Institute: The Human Genetics Programme at the Wellcome Sanger Institute is driving a step-change in our understanding of genetic causes and biological mechan... Cambridgeshire (GB)

Notice NOT-AA-22-009 from the NIH Guide for Grants and Contracts

Notice NOT-AA-22-008 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HL-23-010 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address heart, lung, blood, and sleep (HLBS)-related disorders and diseases. This FOA solicits R33 applications where major feasibility gaps for the enabling technology or transformative platform have already been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage downstream demonstration, utilization and adoption. Well-suited applications must offer the potential to accelerate and/or transform the areas of early detection and screening, model development, clinical diagnosis, treatment, control, prevention or epidemiology, while addressing issues associated with HLBS-related diseases and disorders. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed. This FOA is part of a suite of NHLBI Catalyze program to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Product Definition or Preclinical FOAs.

Funding Opportunity RFA-HL-23-011 from the NIH Guide for Grants and Contracts. This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify and characterize potential therapeutic candidates to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.

Funding Opportunity RFA-HL-23-012 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify a lead compound series toward development of potential therapeutic agents to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.

Funding Opportunity RFA-HL-23-013 from the NIH Guide for Grants and Contracts. This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to develop and test device prototype designs, identify diagnostic disease targets and develop associated assays, and develop research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.

Funding Opportunity RFA-HL-23-014 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of HLBS diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical product optimization and characterization.

Notice NOT-OD-22-066 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-042 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-MH-22-155 from the NIH Guide for Grants and Contracts. Reissue of RFA-MH-20-555. The NIMH Instrumentation Program encourages applications from NIH funded investigators to purchase or upgrade a single commercially available instrument or a group of components to create an instrument that is not commercially available. Examples of instruments that might be submitted under this Funding Opportunity Announcement (FOA) include light microscopes, electron microscopes, spectrophotometers, and biomedical imagers.

Notice NOT-AR-22-016 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-041 from the NIH Guide for Grants and Contracts

Notice NOT-AG-22-012 from the NIH Guide for Grants and Contracts

Notice NOT-AG-22-011 from the NIH Guide for Grants and Contracts

Designs statistical sampling plans, performs data analysis and utilizes statistical tools to review various Quality data.
From General Electric - Sat, 22 Jan 2022 04:42:15 GMT - View all Wisconsin jobs

commensurate with experience (starts at NIH scale): Cincinnati Children's Hospital Medical Center (CCHMC): Fukun Guo, PhD, has an immediate opening in his lab for a postdoctoral Research Fellow in the Division of Experimental Hematology and Cancer Biolog... Cincinnati, Ohio

Notice NOT-OD-22-060 from the NIH Guide for Grants and Contracts